Fig. 5

NOP56 and mTOR converge on a metabolic liability in KRAS-mutant tumor growth. A, Apoptosis assay of H358 and H460 cells expressing control or NOP56-specific shRNAs after treatment with rapamycin (5 μM) for 72 h. Data are presented as mean of three independent experiments (n = 3). *p < 0.05, ****P < 0.0001 and ns P>0.05 by two-way ANOVA with Tukey’s multiple comparisons test. B, H358 and H460 cells expressing control or NOP56-specific shRNAs were treated with rapamycin (5 μM) for 24 h. Cells were then washed, incubated with H2DCFDA for 30 min, and analyzed by flow cytometry. Quantification of relative ROS levels was shown in the right. C, A working model for the function of NOP56 in KRAS-mutant cancers